IDENTIFICATION, CHARACTERIZATION AND COMMERCIAL DEVELOPMENT OF PROTEINS WHOSE EXPRESSION IS ALTERED IN INDIVIDUALS WITH LUNG CANCER

Notice Date

July 30, 2001

Contracting Office

NIH/TDCB, 6120 Executive Blvd., Suite 450, Rockville, MD 20852

ZIP Code

20852

E-Mail Address

Click here to send a message to the CRADA point of (shtroms@mail.nih.gov)

Description

National Cancer Institute Technology Transfer Branch CRADA Opportunity Announcement Summary: The National Cancer Institute (NCI) is currently seeking a Collaborator for a Cooperative Research and Development Agreement (CRADA) to work with investigators in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics (DCEG) to identify proteins which are associated with lung cancer and which can be developed into widely utilized targets for screening or treatment for lung cancer. Proposed NCI Contribution: The NCI is in possession of a number of human biospecimens collected from studies on patients with lung cancer. The biospecimens along with exposure history and clinical data are available for the investigation of protein expression profiles. In addition, the NCI is in the process of performing genotyping assays on these biospecimens to assess the contribution of polymorphisms in cancer-related genes to lung cancer. The NCI has the epidemiological and statistical expertise to examine the protein expression data as it relates to genetic polymorphisms, patient exposure history, and clinical data. Proposed CRADA Collaborator Contribution: The Collaborator will use its proteomics and bioinformatics capabilities to perform a comprehensive high throughput analysis of proteins contained in the biospecimens to identify candidate proteins indicative of lung cancer. The Collaborator will use the identified proteins to design, develop and commercialize diagnostic and/or therapeutic tests for lung cancer. Proposed Joint Contribution: NCI and the Collaborator will jointly design a CRADA research plan and will jointly interpret the data generated under the research plan. Selection Criteria for Choosing the CRADA Collaborator May Include: 1. A demonstrated background and expertise in proteomics and bioinformatics. 2. A demonstrated record of success in the commercial development and production of products related to this area of technology (for example, development of protein-based diagnostic, prognostic or therapeutic kits or tests). 3. The demonstration of adequate resources to perform the protein expression studies and to perform the research and development necessary for commercialization of the resulting inventions. 4. The willingness to commit best effort and demonstrated resources to the research and development of targets for lung cancer. 5. The level of financial and staffing support the CRADA Collaborator will provide for CRADA-related activities. 6. The willingness to cooperate with the NCI in the timely publication of research results. 7. The agreement to be bound by the appropriate Department of Health and Human Services (DHHS) regulations relating to human subject research and to all Public Health Service (PHS) policies relating to the use and care of laboratory animals. 8. The willingness to accept the legal provisions and language of the CRADA. These provisions govern the distribution of future patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor with (1) the grant of a license for research and other Government purposes to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor. Response Procedure: Interested parties should notify the Technology Transfer Branch of the NCI in writing of their interest in the CRADA collaboration no later than August 20, 2001. The written notice should briefly address the selection criteria listed above. Contact Information: CRADA Contact: Svetlana S. Shtrom, Ph.D. 6120 Executive Boulevard, Suite 450 Rockville, Maryland 20852 301-435-1568 or 301-496-0477; FAX 301-402-2117 e-mail: shtroms@mail.nih.gov or CRADA Contact: Kevin Brand, J.D. Fairview Center 1003 W. 7th Street, Suite 502 Frederick, Maryland 21701 301-846-5222 or 301-846-5465; FAX 301-846-6820 e-mail: brandk@mail.nih.gov

Web Link

Click here to view the standard NIH CRADA document. (http://ttb.nci.nih.gov/forms.html)

Record

Loren Data Corp. 20010801/SPMSC027.HTM (W-211 SN50T3H0)